Hepatitis B Virus

Data support initiation of program to boost immune system to fight HBV

Published in Hepatitis Weekly, August 18th, 2003

CellExSys, Inc., a majority owned subsidiary of Targeted Genetics Corporation (TGEN), presented data in support of the anticipated initiation of a phase I clinical trial in patients with chronic hepatitis B.

Results from this study support a novel approach to treatment of this disease, whereby hepatitis B virus (HBV)-specific cytotoxic T lymphocytes (CTL) are isolated and expanded for the purpose of fighting disease.

These data were presented in a poster session at the 38th Annual Meeting of the European Association for the Study of the Liver in Geneva, Switzerland. Susanne C. Schneider, PhD, director of Research at CellExSys, presented these data in...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2003-08-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry